Table 4.
Summary of phase II clinical studies of novel taxane formulations
| Author | Regimen | No. patients |
Outcome |
Toxicity |
||||
|---|---|---|---|---|---|---|---|---|
| RR% | TTP (mos) | PFS% | MS | OS | Grade 3–4 (%) | |||
| Ibrahim et al50 | Nab-paclitaxel 300 mg/m2 q3w | 63 | 48 | 26,6 | 63,6 | Neutropenia g4 (24) Neuropathy g3 (11) |
||
| Blum et al51 | Nab-paclitaxel 100 mg/m2 w | 66 | 20 (RP) | Neutropenia g4 (8) Nausea g4 (4,5) Infection g4 (4,5) |
||||
| Roy et al30 | Nab-paclitaxel 125 mg/m2 w + Gemcitabine 1000 mg/m2 w | 50 | 50 | 60 | 92 | Neutropenia g4 (12) Neutropenia g3 (43) |
||
| Link et al52 | Nab-paclitaxel plus Bevacizumab | 40 | 48,5 | 4,2 | ||||
| Blum et al55 | Nab-paclitaxel 100 mg/m2 w | 181 | 14 | 3 | 9,2 | Neutropenia g4 (<5) | ||
| Nab-paclitaxel 125 mg/m2 w | 16 | 3,5 | 9,1 | |||||
| Schwartzberg et al56 | Nab-paclitaxel 125 mg/m2 w + Capecitabine 825 mg/m2 | 50 | 47,5 | Neutropenia g4 (20) Fatigue g4 (20) |
||||
Abbreviations: TTP, time to progression; MS, median survival; OS overall survival; PFS, progression free survival; RR, response rate; q3w, every 3 weeks; mos, months; w, week; MS, median survival.